[Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients]

What Was Tested

Researchers studied Exenatide in this randomized controlled trial publication.

To study the protective effect of glucagon-like peptide-1 (GLP-1) on the left ventricular diastolic function and endothelial function in patients with type 2 diabetes.

Who Took Part

The study group was 27 patients.

27 patients with type 2 diabetes were randomly divided into two groups: GLP-1 treated group and insulin treated group.

Patients in the GLP-1 group were given GLP-1 analogue and metformin hydrochloride.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.

Patients in the insulin group were given insulin and metformin hydrochloride.

The outcomes of treatments were measured by fasting plasma glucose (FBG) fasting lipid profile, glycosylated hemoglobin (HbA1c), blood pressure and general clinical features.

High resolution Doppler ultrasound was performed to detect mitral early diastolic rapid filling (E-wave), atrial contraction late filling (A-wave), E/A ratio, early diastolic mitral annular velocity (e), late diastolic mitral annular velocity (a), e/a ratio, endothelium-dependent vasodilatation (EDV) mediated by brachial arterial blood flow, and endothelium-independent vasodilatation (EIV) mediated by nitroglycerin.

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Diastole, Exenatide, Glucagon-Like Peptide 1, Glycated Hemoglobin, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized study of Exenatide in 27 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition), a journal based in China.

More context: the Exenatide compound page, all human trials.